AIM ImmunoTech
AIM ImmunoTech Inc. is dedicated to developing solutions that have the potential to help patients across various disease areas, including oncology, immune disorders, and viral diseases. The company focuses on immuno-modulators like Ampligen®, which has shown broad spectrum activity in vitro and animal testing, and is evaluated in clinical studies for debilitating and life-threatening conditions. AIM aims to advance therapeutic solutions and improve lives through innovative research and development.
Industries
Nr. of Employees
small (1-50)
AIM ImmunoTech
Patents
Methods for improving exercise tolerance in myalgic encephalomyelitis patients
US-11813281-B2
View DetailsMethod of reducing antigenic drift or reassortment of viruses in a host animal using α interferon
US-11642396-B2
View DetailsDouble-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US-9315538-B2
View Details
Methods for improving exercise tolerance in myalgic encephalomyelitis patients
US-11813281-B2
View DetailsMethod of reducing antigenic drift or reassortment of viruses in a host animal using α interferon
US-11642396-B2
View DetailsDouble-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US-9315538-B2
View DetailsProducts
Investigational immunomodulator (rintatolimod)
An investigational immunomodulatory therapeutic evaluated in preclinical in vitro and animal models and in early‑phase clinical studies for oncology, immune disorders and viral diseases; studied as monotherapy and in combination with checkpoint inhibitors and vaccines.
Investigational immunomodulator (rintatolimod)
An investigational immunomodulatory therapeutic evaluated in preclinical in vitro and animal models and in early‑phase clinical studies for oncology, immune disorders and viral diseases; studied as monotherapy and in combination with checkpoint inhibitors and vaccines.
Services
Design and execution support for early‑phase clinical trials, IRB coordination, investigator collaborations and combination therapy studies in oncology and immune disorders.
Management of commercial‑scale production runs and coordination with CMOs to produce clinical and commercial lots, including process demonstration batches and supply agreements.
Operational management of expanded access programs including patient access logistics, international distribution and local regulatory coordination.
Engagement with regulatory agencies for designation, export clearance and local approvals; support for submissions and agency interactions.
Support securing funding (including government awards), managing investor communications, and consolidating intellectual property assets to support development programs.
Design and execution support for early‑phase clinical trials, IRB coordination, investigator collaborations and combination therapy studies in oncology and immune disorders.
Management of commercial‑scale production runs and coordination with CMOs to produce clinical and commercial lots, including process demonstration batches and supply agreements.
Operational management of expanded access programs including patient access logistics, international distribution and local regulatory coordination.
Engagement with regulatory agencies for designation, export clearance and local approvals; support for submissions and agency interactions.
Support securing funding (including government awards), managing investor communications, and consolidating intellectual property assets to support development programs.
Expertise Areas
- Immuno‑oncology clinical development
- Clinical trial management (Phase I/II)
- Biologics and therapeutic manufacturing scale‑up
- Regulatory affairs and orphan designation processes
Key Technologies
- TLR3 agonist pharmacology
- Intranasal drug delivery
- Checkpoint inhibitor combination therapy
- Cytokine biomarker assays